The mechanism of Daunorubicin-induced inhibition of prolidase activity in human skin fibroblasts and its implication to impaired collagen biosynthesis

Experimental and Toxicologic Pathology

Volumn 52, Issue 2, 2000, Pages 149-155

  Muszyńska, Anna ^a   PaŁka, Jerzy ^a   Gorodkiewicz, Ewa ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Collagen; Daunorubicin; Fibroblast; Prolidase; Skin human

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; COLLAGEN; DAUNORUBICIN; DIVALENT CATION; MANGANESE; METALLOPROTEINASE; PROLINE; PROLINE DIPEPTIDASE;

ARTICLE; CALCULATION; CATALYSIS; CHILD; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; PH MEASUREMENT; POTENTIOMETRY; SKIN FIBROBLAST; WOUND HEALING;

EID: 17644446471     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(00)80108-6     Document Type: Article

References (31)

1. BERALDO H, GARNIER-SUILLEROT A, TOSI L, LAVELLE F: Iron (III)-adriamycin and iron (III)-daunorubicin complexes: physicochemical characteristics, interaction with DNA, and antitumor activity. Biochemistry 1985; 24: 284-289.
2. BLAND KI, PALIN W E, FRAUNHOFER JA, et al.: Experimental and clinical observations of the effects of cytotoxic chemotherapeutic drugs on wound healing. Ann Surg 1984; 199: 782-790.
3. CALABRESI P, PARKS RE Jr.: Chemotherapy of neoplastic diseases. In: GILMAN AG, GOODMAN LS, GILMAN A (Eds.): The Pharmaco-logical Basis of Therapeutics. Macmillan Publishing Co. New York 1980; 1249-1313.
4. CARMICHAEL J, DEGRAFF WG, GAZDAR AF, et al.: Evaluation of a tetrazolinum-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942.
5. CASAZZA AM: Preclinical selection of new anthracyclines. Cancer Treat Rep 1986; 70: 43-49.
6. CHAMSON A, VOIGTLANDER V, MYARA I, et al.: Collagen biosynthetic anomalies in prolidase deficiency: effect of glycyl-L-proline on the degradation of newly synthesized collagen. Clin Physiol Biochem 1989; 7: 128-136.
7. CHINARD FP: Photometric estimation of proline and ornithine. J Biol Chem 1952; 199: 91-95.
8. DEVEREUX DF, THIBAULT L, BORETOS J, et al.: The quantitative and qualitative impairment of wound healing by adriamycin. Cancer (Phila.) 1979; 43: 932-938.
9. ENDO F, TANOUE A, NAKAI H, et al.: Primary structure and gene localization of human prolidase. J Biol Chem 1989;264: 4476-4481.
10. GOODMAN SI, SOLOMONS CC, MUSCHENHEIM F, et al.: A syndrome resembling lathyrism associated with iminodipeptiduria. Amer J Med 1968; 45: 152-159.
11. INCZEDY J: Complexation Equilibria in Analytical Chemistry, PWN Warszawa 1979 (in Polish).
12. IRVING H, WILLIAMS RJP: The stability of transition -metal complexes. J Chem Soc 1953; 3192-3210.
13. JACKSON SH, DENNIS AN, GREENBERG M: Iminopeptiduria. A genetic defect in recycling collagen: a method for determining prolidase in red blood cells. Can Med Ass J 1975; 113: 759-763.
14. LAEMMLI UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
15. LOWRY OH, ROSENBERGH NI, FARR AL, et al.: Protein measurement with the Folin reagent. J Biol Chem 1951; 265: 193.
16. MAKELA JK, VUORIO T, VUORIO E: Growth-dependent modulation of type I collagen production and mRNA levels in cultured human skin fibroblasts. Biochim Biophys Acta 1990; 1049: 171-176.
17. MILTYK W, KARNA E, PAŁKA J: Inhibition of prolidase activity by non-steroid antiinflammatory drugs in cultured human skin fibroblasts. Pol J Pharmacol 1996; 48: 609-613.
18. MUSZYŃSKA, PAŁKA J, WOŁCZYŃSKI S: Doxorubicin-induced inhibition of prolidase activity in human skin fibroblasts and its implication to impaired collagen biosynthesis. Pol J Pharmacol 1998; 50: 151-157.
19. MYARA I, CHARPENTIER C, GANTIER M, et al.: A cell density affects prolidase and prolinase activity and intracellular amino acid levels in cultured human cells. Clin Chim Acta 1985; 150: 1-9.
20. MYARA I, CHARPENTIER C, LEMONNIER A: Optimal conditions for prolidase assay by proline colorimetric determination: application to imidodipeptiduria. Clin Chim Acta 1982; 125: 193-205.
21. 4 administration inducing liver cytolysis and fibrosis in rat. Brit J Exp Pathol 1987; 68: 7-13.
22. OYAMADA I, PAŁKA J, SCHALK EM, et al.: Scorbutic and fasted guinea pig sera contain an insulin-like growth factor-I reversible inhibitor of proteoglycan and collagen synthesis in chick embryo chondrocytes and adult human skin fibroblasts. Arch Biochem Biophys 1990:276:85-93.
23. PAŁKA JA, KARNA E, MILTYK W: Fibroblast chemotaxis and prolidase activity modulation by insulin-like growth factor II and mannose 6-phosphate. Mol Cell Biochem 1997; 168: 177-183.
24. PAŁKA J, MILTYK W, KARNA E, et al.: Modulation of prolidase activity during in vitro aging of human skin fibroblasts the role of extracellular matrix collagen. Tokai J Exp Clin Med 1996; 21: 207-213.
25. PAŁKA JA, PHANG J: Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors. J Cell Biochem 1997; 67: 166-175.
26. PETERKOFSKY B, CHOJKIER M, BATEMAN J: Determination of collagen synthesis in tissue and cell culture system. In: FURTHMAY M (Ed.): Immunochemistry of the Extracellular Matrix. CRC Press Boca Raton Fl 1982; 19-47.
27. PHANG J M, SCRIVER CR: Disorders of proline and hydroxyproline metabolism. In: SCRIVER CR. BEAUDET AL, SLY WS (Eds.): The Metabolic Basis of Inherited Disease. McGraw Hill New York 1989; 577-597.
28. POWIS G: Metabolism and reactions of quinoid anticancer agents. In: POWIS G (Ed.): Anticancer Drugs: Reactive Metabolism and Drug Interactions. Pergamon Press Ltd. Oxford New York Seoul Tokyo 1994; 273-386.
29. SASAKI T, HOLEYFIELD KC, VITTO J: Doxorubicin-induced inhibition of prolyl hydroxylation during collagen biosynthesis in human skin fibroblast cultures. J Clin Invest 1987; 80: 1735-1741.
30. YARON A, NAIDER F: Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Molec Biol 1993; 28: 31-81.
31. YOUNG RC, OZOLS RF, MYERS CE: Medical progress. The anthracycline antineoplastic drugs. N Engl J Med 1981; 305: 139-153.